skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Coupling of dextrans conjugated with boron to gamma globulin: a model for NCT

Conference ·
OSTI ID:5233832

Our project is to meet more effectively the well known primary requirement for treatment with boron-10 neutron capture therapy (NCT): namely, the selective localization of a sufficient amount of boron in or on target cells. Monoclonal antibodies (MCA) to tumor-associated antigens are attractive targeting carriers for boron-10 in terms of the needed selective localization. However the densities of surface receptors on tumor cells have seemed deficient to achieve successful NCT. If one seeks the necessary radiotherapeutic ratios by increasing the numbers of boron atoms or carborane cages bound per MCA, then inactivation of the antibody can occur through loss of receptor specificity and/or by precipitation of the protein. To achieve the goal of overcoming the limitations of antibody binding capacity, we have elected to use water-soluble dextrans as intermediate carriers. This permits each MCA molecule to target many atoms of boron-10 to the specified antigenic receptors while only 5 to 10 of the amino acid residues of the protein are conjugated by dextrans carrying boron-10.

Research Organization:
Brookhaven National Lab., Upton, NY (USA); Bremen Univ. (Germany, F.R.). Dept. of Chemistry
DOE Contract Number:
AC02-76CH00016
OSTI ID:
5233832
Report Number(s):
BNL-34077; CONF-8310253-1; ON: DE84006538
Resource Relation:
Conference: Symposium on neutron capture therapy, Boston, MA, USA, 12 Oct 1983
Country of Publication:
United States
Language:
English